News Importance of Brain Shrinkage for MS Treatment Measure Focus of Novartis Presentation Importance of Brain Shrinkage for MS Treatment Measure Focus of Novartis Presentation by Patricia Silva, PhD | September 3, 2014 Share this article: Share article via email Copy article link Novartis has announced that it will present new analyses and redefinedĀ treatment goals for multiple sclerosis (MS) at theĀ 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS), which is taking place in Boston, between September 10 and 13. Novartis claims to have data that shows the importance of brain shrinkage, as well as the importance of including the parameterĀ as a fourth key measure of MS. Treating multiple sclerosis is aimed at registering “no evidence of disease activity” or “NEDA,” which means having no evidence of relapses, MRI lesions, and disability progression. However, Novartis is presenting clinical results that reveal the importance of brain volume loss. The trials performed by the pharmaceutical company show thatĀ patients treated with Gilenya (fingolimod) were more likely to achieve NEDA based on assessment of the four key measures, including MS-related brain shrinkage, than patients treated with placebo. “The data at ACTRIMS-ECTRIMS will reinforce the role of brain shrinkage and its association with future long-term MS disability progression,” explained theĀ global head of development of Novartis Pharmaceuticals,Ā Vasant Narasimhan. “Novartis is committed to improving treatment outcomes for people with MS, and we believe that by including brain shrinkage as part of NEDA, clinicians can gain a more complete understanding of disease progression and treatment effects.” Although human brain volume loss is a normal process that happens with age, patients who suffer from MS experience brain shrinkage three to five times faster. The process starts in early stages of the disease, before symptoms are even perceptible and is related to theĀ Ā loss of physical and cognitive functions as well. [adrotate group=”4″] According to the company, the trials that will be displayed during four oral presentations reveal the connection between brain shrinkage andĀ future long-term disability progression in patients with MS, as well as that patients with relapsing MS treated with Gilenya had lower rates of brain shrinkage, which were importantly sustained over time. The biotechnology company Synthetic Biologics also already announced that is presenting its latest dataĀ regarding cognitive and disability measures in women with MS at theĀ ACTRIMS-ECTRIMS Meeting. The company isĀ developing novel drug candidates targeting specific pathogens that cause serious infections and diseases, with an emphasis forĀ Trimesta, an investigational oral estriol that is being evaluated in combination with Copaxone (glatiramer acetate injection)Ā in a randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of relapsing-remitting MS in women. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags 2014 ACTRIMS-ECTRIMS Meeting, brain shrinkage, Gilenya, Novartis
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program